Can Breast Cancer Be Prevented?

References

1. ↵
   1. Gail M. H.,
   2. Brinton L. A.,
   3. Byar D. P.

   (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886, pmid:2593165.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Fisher B.,
   2. Redmond C.

   (1991) New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent [editorial]. J Natl Cancer Inst 83:1278–1280, pmid:1832192.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Fisher B.,
   2. Costantino J. P.,
   3. Wickerham D. L.

   (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388, pmid:9747868.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Cummings S. R.,
   2. Norton L.,
   3. Eckert S.

   (1998) Raxolifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial [abstract]. Proc Am Soc Clin Oncol 17:2, a.

   OpenUrl
5. ↵
   1. Cummings S. R.,
   2. Eckert S.,
   3. Krueger K. A.

   (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197, pmid:10376571.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Ettinger B.,
   2. Black D. M.,
   3. Mitlak B. H.

   (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigations. JAMA 282:637–645, pmid:10517716.

   OpenUrlCrossRefPubMedWeb of Science